GO
Loading...

Myriad Genetics Inc

More

  • Options Eye Alzheimer's, GM, AmeriCredit Thursday, 19 Jun 2008 | 8:26 AM ET

    Options are eyeing the drug sector's Alzheimer's treatments, according to one observer.

  • Dow Headed Below 12,000? Wednesday, 18 Jun 2008 | 5:48 PM ET

    Stocks closed lower again on Wednesday. For a time, the Dow traded below the 12,000 mark for the first time since mid-March. What's the "Word on the Street?"

  • Medical Breakthrough Boom Tuesday, 17 Jun 2008 | 6:11 PM ET

    On Tuesday we received word of three exciting medical advancements. Find out what’s happening and how to trade them.

  • Triage Trade: Pfizer Wednesday, 9 Apr 2008 | 6:33 PM ET

    Pfizer treats us for everything from high cholesterol to impotence but in an ironic twist, it’s very sick itself. What’s the prescription for getting shares of Pfizer out of triage?

  • Your First Move For Wednesday Apr. 9th Tuesday, 8 Apr 2008 | 6:51 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Stocks Fall on Recession Fears Tuesday, 8 Apr 2008 | 6:16 PM ET

    Plus, Intel drags down tech, breaking news from American Airlines and UPS and much more.

  • Alzheimer's Miracle? Monday, 7 Apr 2008 | 6:33 PM ET

    Shares of Wyeth and Elan surged Monday on the promise of a new Alzheimer's drug. Can you trade it?

  • Double In A Decade Tuesday, 26 Feb 2008 | 6:21 PM ET

    Healthcare spending is expected to nearly double to $4.3 trillion by 2017. Who’s most likely to benefit and can you trade it?

  • Your Health, Your Trade Wednesday, 10 Oct 2007 | 11:01 PM ET

    BREAKING: Reuters reports FDA panel backs drug-coated stents made by Medtronic (MDT).

  • Promising Drug Headlines Tuesday, 25 Sep 2007 | 11:32 AM ET

    Look for pharmaceutical and biotech companies to make news this week as a UBS industry conference kicks off in New York. Also, Merrill Lynch analysts believe pricing power for prescription drugs is returning. What’s the trade?

  • Neurochem And Alzheimer's: Breaking Code Not Easy Monday, 27 Aug 2007 | 2:35 PM ET

    Shares of Neurochem today are trading at a new low after the Canadian biotech announced its developmental drug for Alzheimer's didn't work well enough. It is the latest evidence that cracking the code of this complex disease is extremely challenging. We recently did a story on the drug called Alzhemed, the potential AD-drug market and other companies working on treatments/cures at a dementia conference in Washington, DC.